Data updated: May 26, 2026
RETEVMO (selpercatinib)
Rearranged during Transfection (RET) Inhibitors Genetically Validated
Trial Activity: Stable 13 active trials
Orphan Drug Breakthrough Therapy Priority Review Accelerated Approval
Oncology
Approved 2020-05-08
RETEVMO is indicated for the treatment of Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Thyroid Cancer; Solid Tumors.
How RETEVMO Works
Selpercatinib functions as a kinase inhibitor that targets wild-type and multiple mutated isoforms of the RET protein. In certain cancers, RET gene fusions or point mutations create constitutively active proteins that drive tumor cell proliferation. By inhibiting these proteins, selpercatinib demonstrates anti-tumor activity across various models of RET-driven disease. The drug also inhibits other targets, including VEGFR and FGFR, at clinically achievable concentrations.
Development Insights
Eli Lilly and Company conducting 15 trials (52%)
90 indications explored (Broad Platform)
→ healthy (15 trials)
→ medullary thyroid cancer (3 trials)
→ recurrent ependymoma (2 trials)
7
Indications
--
Phase 3 Trials
4
Priority Reviews
6
Years on Market
Details
- Status
- Prescription
- First Approved
- 2020-05-08
- Patent Cliff
- 2039
- Routes
- ORAL
- Dosage Forms
- CAPSULE, TABLET
RETEVMO Approval History
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
66 FDA actions from 2020 to 2025 · 5 indication expansions
What RETEVMO Treats
4 indicationsRETEVMO is approved for 4 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Non-Small Cell Lung Cancer
- Medullary Thyroid Cancer
- Thyroid Cancer
- Solid Tumors
Source: FDA Label
RETEVMO Target & Pathway
ProTarget
RETEVMO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
10
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
6
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
10
Same indication, different mechanism — what else might this patient receive?
Unlock 20 more competitors across all three rings.
Upgrade to Pro Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in RETEVMO's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications RETEVMO treats. First-in-class if their pivotal trials read out positive.
Tiragolumab MTIG7192A / RG6058 ~ Mixed — Ph3 readout
Hoffmann-La Roche TIGIT · monoclonal antibody (anti-TIGIT) · 10 Phase 3 trials
Ceralasertib AZD6738 ~ Mixed — Ph3 readout
AstraZeneca ATR · small-molecule ATR kinase inhibitor · 2 Phase 3 trials
Uliledlimab TJ004309
TJ Biopharma Co., Ltd. NT5E · monoclonal antibody (anti-CD73) · 1 Phase 3 trial
Drugs Similar to RETEVMO
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
AUGTYRO
REPOTRECTINIB
Bristol-Myers Squibb
Shared indications:
Non-Small Cell Lung CancerSolid Tumors
TAFINLAR
DABRAFENIB MESYLATE
Novartis
Shared indications:
Non-Small Cell Lung CancerSolid Tumors
📋
Clinical Trial Registry
29 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03155620 results posted | NCI-2017-01251 NCI-2017-01251, APEC1621SC | Ph 2 | active not recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
| NCT04320888 results posted | NCI-2020-01756 NCI-2020-01756, APEC1621N | Ph 2 | active not recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial |
| NCT04280081 LIBRETTO-321 results posted | 17492 J2G-GH-JZJK | Ph 2 | active not recruiting | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation |
| NCT04268550 | S1900B NCI-2019-08097, S1900B | Ph 2 | active not recruiting | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) |
| NCT04211337 LIBRETTO-531 results posted | 17478 J2G-MC-JZJB, 2019-001978-28 | Ph 3 | active not recruiting | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer |
| NCT04819100 LIBRETTO-432 | 18126 J2G-MC-JZJX, 2020-005191-35 | Ph 3 | active not recruiting | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) |
| NCT03899792 LIBRETTO-121 results posted | 17493 J2G-OX-JZJJ, LOXO-RET-18036 | Ph 1, Ph 2 | active not recruiting | A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors |
| NCT05469113 results posted | 17754 J2G-OX-JZJS, LOXO-RET-18026 | Ph 1 | completed | A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants |
| NCT04759911 | 2020-0570 NCI-2021-00535, 2020-0570 | Ph 2 | active not recruiting | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer |
| NCT04194944 LIBRETTO-431 results posted | 17479 J2G-MC-JZJC, 2019-001979-36 | Ph 3 | active not recruiting | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |
| NCT05338476 results posted | 17753 J2G-OX-JZJR, LOXO-RET-18017 | Ph 1 | completed | A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants |
| NCT05338489 results posted | 17751 J2G-OX-JZJP, LOXO-RET-18014 | Ph 1 | completed | A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants |
| NCT05468164 results posted | 17752 J2G-MC-JZJQ, LOXO-RET-18015 | Ph 1 | completed | A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants |
| NCT05630274 results posted | 17486 J2G-OX-JZJG, LOXO-RET-18032 | Ph 1 | completed | A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants |
| NCT05469100 results posted | 17484 J2G-OX-JZJE, LOXO-RET-18023 | Ph 1 | completed | A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function |
| NCT05906836 results posted | 18727 J2G-MC-JZPB | Ph 1 | completed | A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants |
| NCT07010393 | Real-Neo | Ph 4 | not yet recruiting | Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study |
| NCT05338515 results posted | 17485 J2G-OX-JZJF, LOXO-RET-18057 | Ph 1 | completed | A Study of Selpercatinib (LY3527723) in Healthy Participants |
| NCT05630287 results posted | 17768 J2G-OX-JZJT, LOXO-RET-18016 | Ph 1 | completed | A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants |
| NCT05436912 results posted | 17483 J2G-OX-JZJD, LOXO-RET-18022 | Ph 1 | completed | A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants |
| NCT05324124 results posted | 18178 J2G-MC-JZPA | Ph 1 | completed | A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants |
| NCT05089019 results posted | 18177 J2G-MC-JZJZ | Ph 1 | completed | A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants |
| NCT05136404 results posted | 17821 J2G-MC-JZJU | Ph 1 | completed | A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants |
| NCT03944772 ORCHARD | D6186C00001 2023-504624-25-00, 2018-003974-29 | Ph 2 | active not recruiting | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) |
| NCT05668962 | 22-018 | Ph 2 | recruiting | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC |
| NCT05338502 results posted | 17574 J2G-OX-JZJL, LOXO-RET-19075 | Ph 1 | completed | Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants |
| NCT05364645 | S1900F NCI-2022-02517, S1900F | Ph 2 | withdrawn | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer |
| NCT04782076 results posted | 17972 J2G-MC-JZJV | Ph 1 | completed | A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants |
| NCT02925234 DRUP | M15DRU | Ph 2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RETEVMO FDA Label Details
Indications & Usage
FDA Label (PDF)RETEVMO is indicated for the treatment of Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Thyroid Cancer; Solid Tumors.
View full patent landscape →
12 OB patents · 3 families ·
142 international docs across 42 countries
RETEVMO Patents & Exclusivity
Latest Patent: Apr 2039
Exclusivity: Nov 2031
Patents (12 active)
US12138250*PED
Expires Apr 10, 2039
US10786489*PED
Expires Apr 10, 2039
US10584124*PED
Expires Apr 10, 2039
US12138250
Expires Oct 10, 2038
US10584124
Expires Oct 10, 2038
US10786489
Expires Oct 10, 2038
US10112942*PED
Expires Apr 10, 2038
US10137124*PED
Expires Apr 10, 2038
US10172851*PED
Expires Apr 10, 2038
US10172851
Expires Oct 10, 2037
US10137124
Expires Oct 10, 2037
US10112942
Expires Oct 10, 2037
Exclusivity
M-311
Until Sep 2027
M-312
Until Sep 2027
NPP
Until May 2027
ODE-301
Until May 2027
ODE-302
Until May 2027
ODE-303
Until May 2027
ODE-409
Until Sep 2029
ODE-412
Until Sep 2029
ODE-484
Until May 2031
ODE-485
Until May 2031
ODE-487
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
NPP
Until May 2027
ODE-301
Until May 2027
ODE-302
Until May 2027
ODE-303
Until May 2027
ODE-409
Until Sep 2029
ODE-412
Until Sep 2029
ODE-484
Until May 2031
ODE-485
Until May 2031
ODE-487
Until May 2031
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
NPP
Until May 2027
ODE-301
Until May 2027
ODE-302
Until May 2027
ODE-303
Until May 2027
ODE-409
Until Sep 2029
ODE-412
Until Sep 2029
ODE-484
Until May 2031
ODE-485
Until May 2031
ODE-487
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
NPP
Until May 2027
ODE-301
Until May 2027
ODE-302
Until May 2027
ODE-303
Until May 2027
ODE-409
Until Sep 2029
ODE-412
Until Sep 2029
ODE-484
Until May 2031
ODE-485
Until May 2031
ODE-487
Until May 2031
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until Sep 2029
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
M-311
Until Sep 2027
M-312
Until Sep 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
ODE*
Until May 2027
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until May 2027
ODE*
Until May 2031
ODE*
Until Sep 2029
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Mar 2028
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Nov 2031
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Mar 2030
PED
Until Mar 2030
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
PED
Until Nov 2027
Source: FDA Orange Book
Pro Intelligence Preview
Deep insights for RETEVMO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2039
- • 516 active patents
Trial Analysis
- • 29 total trials
- • Stage: Stable
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment